{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-090875","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.145247+00:00","generated_at":"2026-06-11T10:54:10.231569+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Leap Therapeutics Q2 net loss $13.4M; DKN-01 CRC trial advances to Part B","bullets":["Net loss $13.4M in Q2 2023 vs $17.0M in Q2 2022; R&D expenses fell to $11.1M.","Cash and equivalents $91.4M at June 30, 2023; interest income $1.2M.","DeFianCe Part A CRC study achieved >20% ORR; 130-patient randomized Part B initiated.","DisTinGuish GEA data: 73% ORR (mITT), median OS 19.5 months, median PFS 11.3 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-090875","json":"https://secwatch.observer/filing/0001104659-23-090875.json","markdown":"https://secwatch.observer/filing/0001104659-23-090875.md","text":"https://secwatch.observer/filing/0001104659-23-090875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/0001104659-23-090875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/tm2323558d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:54:10.231569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fed69b5ae00ebbf8d10b3c8ed41f64ad7c2237a","claim":"CYPHERPUNK TECHNOLOGIES INC. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/0001104659-23-090875-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}